{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T16:01:14Z","timestamp":1787500874690,"version":"build-2736575974"},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T00:00:00Z","timestamp":1709164800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca PLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Health Policy OPEN"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.hpopen.2024.100116","type":"journal-article","created":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T11:59:19Z","timestamp":1709294359000},"page":"100116","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["The evolving value assessment of cancer therapies: Results from a modified Delphi study"],"prefix":"10.1016","volume":"6","author":[{"given":"Myrto","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4678-6048","authenticated-orcid":false,"given":"Hugo","family":"Larose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Gr\u00e4beldinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-2767-5651","authenticated-orcid":false,"given":"Jon","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Marie","family":"Baird","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Bruns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7623-1583","authenticated-orcid":false,"given":"Javier","family":"Cortes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1781-2518","authenticated-orcid":false,"given":"Giuseppe","family":"Curigliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Ferris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis P.","family":"Garrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.K.","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravindran","family":"Kanesvaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0823-8086","authenticated-orcid":false,"given":"Gary","family":"Lyman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Pani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zack","family":"Pemberton-Whiteley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas","family":"Salmonson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Sawicki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry","family":"Stein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Churl","family":"Suh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Galina","family":"Velikova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Grueger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.hpopen.2024.100116_b0005","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21654","article-title":"Cancer statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"Ca Cancer J Clin"},{"issue":"10","key":"10.1016\/j.hpopen.2024.100116_b0010","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1093\/annonc\/mdt301","article-title":"Cancer mortality in Europe, 2005\u20132009, and an overview of trends since 1980","volume":"24","author":"Bosetti","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.hpopen.2024.100116_b0015","unstructured":"Canadian Cancer Society. Canadian Cancer Statistics. [Available from: <https:\/\/cancer.ca\/en\/research\/cancer-statistics\/canadian-cancer-statistics>. Accessed 21 November 2022."},{"issue":"2","key":"10.1016\/j.hpopen.2024.100116_b0020","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.soncn.2017.02.002","article-title":"Cancer screening and early detection in the 21st century","volume":"33","author":"Loud","year":"2017","journal-title":"Semin Oncol Nurs"},{"key":"10.1016\/j.hpopen.2024.100116_b0025","unstructured":"World Health Organization. Early cancer diagnosis saves lives, cuts treatment costs. 2017 [Available from: <https:\/\/www.who.int\/news\/item\/03-02-2017-early-cancer-diagnosis-saves-lives-cuts-treatment-costs>. Accessed 22 August 2023."},{"key":"10.1016\/j.hpopen.2024.100116_b0030","unstructured":"US National Cancer Institute. Cancer trends progress report [Available from: <https:\/\/progressreport.cancer.gov\/diagnosis\/stage>. Accessed 22 August 2023."},{"issue":"7782","key":"10.1016\/j.hpopen.2024.100116_b0035","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41586-019-1730-1","article-title":"A view on drug resistance in cancer","volume":"575","author":"Vasan","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.hpopen.2024.100116_b0040","unstructured":"National Institute for Health and Care Excellence (NICE). Annex 7: health technology assessment process [Available from: <https:\/\/www.nice.org.uk\/Media\/Default\/About\/what-we-do\/Life-sciences\/evaluation-framework.pdf>. Accessed 22 August 2023."},{"key":"10.1016\/j.hpopen.2024.100116_b0045","unstructured":"ICER. 2020-2023 value assessment framework 2020 [Available from: <https:\/\/icer.org\/wp-content\/uploads\/2020\/10\/ICER_2020_2023_VAF_102220.pdf>. Accessed 22 August 2023."},{"key":"10.1016\/j.hpopen.2024.100116_b0050","doi-asserted-by":"crossref","first-page":"8457","DOI":"10.2147\/CMAR.S328058","article-title":"The impasse on overall survival in oncology reimbursement decision-making: how can we resolve this?","author":"Lux","year":"2021","journal-title":"Cancer Manag Res"},{"issue":"2","key":"10.1016\/j.hpopen.2024.100116_b0055","first-page":"88","article-title":"Post-study therapy as a source of confounding in survival analysis of first-line studies in patients with advanced non-small-cell lung cancer","volume":"3","author":"Zietemann","year":"2011","journal-title":"J Thorac Dis"},{"issue":"3","key":"10.1016\/j.hpopen.2024.100116_b0060","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/annonc\/mdv562","article-title":"Statistical controversies in clinical research: end points other than overall survival are vital for regulatory approval of anticancer agents","volume":"27","author":"Saad","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.hpopen.2024.100116_b0065","first-page":"S5","article-title":"Looking beyond survival data: how should we assess innovation in oncology reimbursement decision making","author":"Fameli","year":"202395","journal-title":"Values & Outcomes Spotlight"},{"issue":"6","key":"10.1016\/j.hpopen.2024.100116_b0070","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.respe.2008.09.006","article-title":"M\u00e9thodes de consensus: revue des m\u00e9thodes originales et de leurs grandes variantes utilis\u00e9es en sant\u00e9 publique","volume":"56","author":"Bourr\u00e9e","year":"2008","journal-title":"Rev Epidemiol Sante Publique"},{"issue":"9","key":"10.1016\/j.hpopen.2024.100116_b0075","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1093\/annonc\/mdw233","article-title":"Relative effectiveness assessments of oncology medicines for pricing and reimbursement decisions in european countries","volume":"27","author":"Kleijnen","year":"2016","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.hpopen.2024.100116_b0080","doi-asserted-by":"crossref","first-page":"1562861","DOI":"10.1080\/20016689.2018.1562861","article-title":"Perspectives to mitigate payer uncertainty in health technology assessment of novel oncology drugs","volume":"7","author":"Sol\u00e0-Morales","year":"2019","journal-title":"J Mark Access Health Policy"},{"key":"10.1016\/j.hpopen.2024.100116_b0085","doi-asserted-by":"crossref","DOI":"10.7573\/dic.212507","article-title":"Approving cancer treatments based on endpoints other than overall survival: an analysis of historical data using the PACE continuous innovation INDICATORS\u2122(CII)","volume":"6","author":"Brooks","year":"2017","journal-title":"Drugs in Context"},{"issue":"1","key":"10.1016\/j.hpopen.2024.100116_b0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/13696998.2021.2009711","article-title":"Oncology drugs and added benefit: insights from 3 european health technology assessment agencies on the role of efficacy endpoints","volume":"25","author":"Smith","year":"2022","journal-title":"J Med Econ"},{"issue":"7","key":"10.1016\/j.hpopen.2024.100116_b0095","first-page":"1","article-title":"Endpoints in oncology clinical trials","volume":"23","author":"Kilickap","year":"2018","journal-title":"J buon"},{"key":"10.1016\/j.hpopen.2024.100116_b0100","unstructured":"European Medicines Agency. The role of the pathological complete response as an endpoint in neoadjuvant breast cancer studies 2014 [Available from: <https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/draft-guideline-role-pathological-complete-response-endpoint-neoadjuvant-breast-cancer-studies_en.pdf>. Accessed 22 August 2023."},{"key":"10.1016\/j.hpopen.2024.100116_b0105","unstructured":"Food and Drug Administration. Pathological Complete Response in Neoadjuvant Treatment of High-Risk Early-Stage Breast Cancer: Use as an Endpoint to Support Accelerated Approval Guidance for Industry 2020 [Available from: <https:\/\/www.fda.gov\/media\/83507\/download>. Accessed 22 August 2023."},{"issue":"2","key":"10.1016\/j.hpopen.2024.100116_b0110","doi-asserted-by":"crossref","first-page":"188","DOI":"10.18632\/oncotarget.27418","article-title":"Circulating tumor DNA analysis in the era of precision oncology","volume":"11","author":"Said","year":"2020","journal-title":"Oncotarget"},{"key":"10.1016\/j.hpopen.2024.100116_b0115","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.breast.2022.07.010","article-title":"The circulating tumor DNA (ctDNA) alteration level predicts therapeutic response in metastatic breast cancer: novel prognostic indexes based on ctDNA","volume":"65","author":"Liu","year":"2022","journal-title":"Breast"},{"issue":"6","key":"10.1016\/j.hpopen.2024.100116_b0120","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1093\/annonc\/mdz085","article-title":"Early ctDNA dynamics as a surrogate for progression-free survival in advanced breast cancer in the BEECH trial","volume":"30","author":"Hrebien","year":"2019","journal-title":"Ann Oncol"},{"issue":"17","key":"10.1016\/j.hpopen.2024.100116_b0125","doi-asserted-by":"crossref","first-page":"9527","DOI":"10.3390\/ijms23179527","article-title":"Monitoring circulating tumor DNA in untreated non-small-cell lung cancer patients","volume":"23","author":"Ryu","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"19","key":"10.1016\/j.hpopen.2024.100116_b0130","doi-asserted-by":"crossref","first-page":"4954","DOI":"10.3390\/cancers14194954","article-title":"Prognostic value of circulating tumor DNA (ctDNA) in oncogene-driven NSCLC: current knowledge and future perspectives","volume":"14","author":"Zografos","year":"2022","journal-title":"Cancers"},{"issue":"10","key":"10.1016\/j.hpopen.2024.100116_b0135","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1158\/2767-9764.CRC-22-0258","article-title":"Circulating tumor DNA monitoring reveals molecular progression before radiologic progression in a real-life cohort of patients with advanced non\u2013small cell lung cancer","volume":"2","author":"Frank","year":"2022","journal-title":"Cancer research communications"},{"key":"10.1016\/j.hpopen.2024.100116_b0140","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3389\/fphar.2017.00171","article-title":"Managed entry agreements for oncology drugs: lessons from the european experience to inform the future","volume":"8","author":"Pauwels","year":"2017","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.hpopen.2024.100116_b0145","unstructured":"Gemeinsamer Bundesausschuss. Anwendungsbegleitende Datenerhebung bei neuen Arzneimitteln [Available from: https:\/\/www.g-ba.de\/themen\/arzneimittel\/arzneimittel-richtlinie-anlagen\/anwendungsbegleitende-datenerhebung\/. Accessed 7 February 2024."},{"key":"10.1016\/j.hpopen.2024.100116_b0150","unstructured":"Services CfMM. Coverage with Evidence Development [Available from: https:\/\/www.cms.gov\/medicare\/coverage\/evidence. Accessed 7 February 2024."},{"issue":"3","key":"10.1016\/j.hpopen.2024.100116_b0155","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.jval.2011.12.013","article-title":"Coverage with evidence development, only in research, risk sharing, or patient access scheme? a framework for coverage decisions","volume":"15","author":"Walker","year":"2012","journal-title":"Value Health"},{"key":"10.1016\/j.hpopen.2024.100116_b0160","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.699466","article-title":"The evolution of AIFA registries to support managed entry agreements for orphan medicinal products in Italy","volume":"12","author":"Xoxi","year":"2021","journal-title":"Front Pharmacol"},{"issue":"5","key":"10.1016\/j.hpopen.2024.100116_b0165","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.jval.2013.04.011","article-title":"Performance-based risk-sharing arrangements\u2014good practices for design, implementation, and evaluation: report of the ISPOR good practices for performance-based risk-sharing arrangements task force","volume":"16","author":"Garrison","year":"2013","journal-title":"Value Health"},{"key":"10.1016\/j.hpopen.2024.100116_b0170","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s41669-020-00235-6","article-title":"Investigation of factors considered by health technology assessment agencies in eight countries","volume":"5","author":"Yuasa","year":"2021","journal-title":"PharmacoEconomics-Open"},{"key":"10.1016\/j.hpopen.2024.100116_b0175","unstructured":"ISPOR. Value Assessment Frameworks [Available from: <https:\/\/www.ispor.org\/strategic-initiatives\/value-assessment-frameworks>. Accessed 22 August 2023."},{"issue":"2","key":"10.1016\/j.hpopen.2024.100116_b0180","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.jval.2017.12.012","article-title":"A health economics approach to US value assessment frameworks\u2014introduction: an ISPOR special task force report [1]","volume":"21","author":"Neumann","year":"2018","journal-title":"Value Health"},{"key":"10.1016\/j.hpopen.2024.100116_b0185","article-title":"Novel elements of the value flower: fake or truly novel?","volume":"01","author":"Garrison","year":"2021","journal-title":"Signal"},{"key":"10.1016\/j.hpopen.2024.100116_b0190","unstructured":"National Institutes of Health. Transformative Research to Address Health Disparities and Advance Health Equity [Available from: <https:\/\/commonfund.nih.gov\/healthdisparitiestransformation>. Accessed 22 August 2023."},{"issue":"7","key":"10.1016\/j.hpopen.2024.100116_b0195","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1002\/hec.3899","article-title":"Do cancer treatments have option value? real-world evidence from metastatic melanoma","volume":"28","author":"Li","year":"2019","journal-title":"Health Econ"},{"key":"10.1016\/j.hpopen.2024.100116_b0200","unstructured":"European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP) Guideline on the Clinical Evaluation of Anticancer Medicinal Products 2019 [Available from: <https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/draft-guideline-evaluation-anticancer-medicinal-products-man-revision-6_en.pdf>. Accessed 22 August 2023."},{"key":"10.1016\/j.hpopen.2024.100116_b0205","doi-asserted-by":"crossref","DOI":"10.1177\/17588359211059587","article-title":"Surrogate endpoints for early-stage breast cancer: a review of the state of the art, controversies, and future prospects","volume":"13","author":"Gion","year":"2021","journal-title":"Therapeutic advances in medical oncology"},{"issue":"18","key":"10.1016\/j.hpopen.2024.100116_b0210","doi-asserted-by":"crossref","first-page":"3342","DOI":"10.1016\/j.ejca.2012.05.023","article-title":"Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy","volume":"48","author":"Houssami","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.hpopen.2024.100116_b0215","unstructured":"Friends of Cancer Research. Assessing the Use of ctDNA as an Early Endpoint in Early-Stage Disease. Friends of Cancer Research Annual Meeting 2021 2021 [Available from: <https:\/\/friendsofcancerresearch.org\/wp-content\/uploads\/Assessing_Use_of_ctDNA_Early_Endpoint_Early-Stage_Disease.pdf>. Accessed 22 August 2023."},{"key":"10.1016\/j.hpopen.2024.100116_b0220","unstructured":"Food and Drug Administration. Use of Circulating Tumor DNA for Early-Stage Solid Tumor Drug Development Guidance for Industry (Draft Guidance) 2022 [Available from: <https:\/\/www.fda.gov\/media\/158072\/download>. Accessed 22 August 2023."},{"key":"10.1016\/j.hpopen.2024.100116_b0225","unstructured":"Haute autorit\u00e9 de sant\u00e9. Autorisation d\u2019acc\u00e8s Pr\u00e9coce Aux M\u00e9dicaments : Doctrine d\u2019\u00e9valuation de La HAS 2021 [Available from: <https:\/\/www.has-sante.fr\/upload\/docs\/application\/pdf\/2021-06\/acces_precoces_-_doctrine.pdf >. Accessed 22 August 2023."},{"key":"10.1016\/j.hpopen.2024.100116_b0230","unstructured":"NHS. Cancer Drugs Fund [Available from: <https:\/\/www.england.nhs.uk\/cancer\/cdf\/> Accessed 22 August 2023."},{"key":"10.1016\/j.hpopen.2024.100116_b0235","unstructured":"NHS. Apply for the early access to medicines scheme (EAMS) 2014 [Available from: <https:\/\/www.gov.uk\/guidance\/apply-for-the-early-access-to-medicines-scheme-eams>. Accessed 22 August 2023."},{"issue":"9","key":"10.1016\/j.hpopen.2024.100116_b0240","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/j.techfore.2011.04.005","article-title":"Enhancing rigour in the Delphi technique research","volume":"78","author":"Hasson","year":"2011","journal-title":"Technol Forecast Soc Chang"},{"issue":"2","key":"10.1016\/j.hpopen.2024.100116_b0245","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jval.2017.12.007","article-title":"Defining elements of value in health care\u2014a health economics approach: an ISPOR special task force report [3]","volume":"21","author":"Lakdawalla","year":"2018","journal-title":"Value Health"},{"issue":"24","key":"10.1016\/j.hpopen.2024.100116_b0250","doi-asserted-by":"crossref","first-page":"2925","DOI":"10.1200\/JCO.2016.68.2518","article-title":"Updating the American Society of Clinical Oncology value framework: revisions and reflections in response to comments received","volume":"34","author":"Schnipper","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hpopen.2024.100116_b0255","unstructured":"ESMO. ESMO: Magnitude of clinical benefit scale [Available from: <https:\/\/www.esmo.org\/guidelines\/esmo-mcbs>. Accessed 22 August 2023."},{"key":"10.1016\/j.hpopen.2024.100116_b0260","unstructured":"The Council on Quality and Leadership. CMS Includes CQL\u2019s Personal Outcome Measures\u00ae In HCBS Quality Measure Set 2022 [Available from: <https:\/\/www.c-q-l.org\/resources\/articles\/cms-includes-cqls-personal-outcome-measures-in-hcbs-quality-measure-set\/>. Accessed 22 August 2023."},{"issue":"1","key":"10.1016\/j.hpopen.2024.100116_b0265","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s12955-022-01987-x","article-title":"Patient reported outcomes in oncology: changing perspectives\u2014a systematic review","volume":"20","author":"Silveira","year":"2022","journal-title":"Health Qual Life Outcomes"},{"issue":"2","key":"10.1016\/j.hpopen.2024.100116_b0270","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1016\/S1470-2045(19)30790-9","article-title":"International standards for the analysis of quality-of-life and patient-reported outcome endpoints in cancer randomised controlled trials: recommendations of the SISAQOL consortium","volume":"21","author":"Coens","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.hpopen.2024.100116_b0275","unstructured":"Rare Cancers Australia and CanTeen. Counting the Cost 2022 [Available from: <https:\/\/www.canteen.org.au\/sites\/default\/files\/2022-09\/RCA4279_Counting_the_Cost_Report_FINAL.pdf>. Accessed 22 August 2023."},{"key":"10.1016\/j.hpopen.2024.100116_b0280","unstructured":"EuroQol Group. EQ-5D-5L [Available from: <https:\/\/euroqol.org\/eq-5d-instruments\/eq-5d-5l-about\/>. Accessed 22 August 2023."},{"key":"10.1016\/j.hpopen.2024.100116_b0285","doi-asserted-by":"crossref","DOI":"10.1016\/j.socscimed.2019.112595","article-title":"Multiple criteria decision analysis for HTA across four EU member states: piloting the advance value framework","volume":"246","author":"Angelis","year":"2020","journal-title":"Soc Sci Med"},{"issue":"3","key":"10.1016\/j.hpopen.2024.100116_b0290","doi-asserted-by":"crossref","first-page":"30","DOI":"10.3390\/data2030030","article-title":"Estimating cost savings from early cancer diagnosis","volume":"2","author":"Kakushadze","year":"2017","journal-title":"Data"},{"key":"10.1016\/j.hpopen.2024.100116_b0295","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ejca.2020.01.011","article-title":"The cost of cancer in Europe 2018","volume":"129","author":"Hofmarcher","year":"2020","journal-title":"Eur J Cancer"}],"container-title":["Health Policy OPEN"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590229624000017?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590229624000017?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,16]],"date-time":"2024-06-16T18:44:57Z","timestamp":1718563497000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590229624000017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":59,"alternative-id":["S2590229624000017"],"URL":"https:\/\/doi.org\/10.1016\/j.hpopen.2024.100116","relation":{},"ISSN":["2590-2296"],"issn-type":[{"value":"2590-2296","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The evolving value assessment of cancer therapies: Results from a modified Delphi study","name":"articletitle","label":"Article Title"},{"value":"Health Policy OPEN","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hpopen.2024.100116","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"100116"}}